Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 2
1(25.0%)
4Total
N/A(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02054689Not ApplicableCompleted

Fractionated Stereotactic Radiosurgery for Large Brain Metastases

Role: lead

NCT01345539Phase 2Terminated

Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation

Role: lead

NCT01345552Not ApplicableCompleted

Radiosurgery for Patients Recurrent Oligometastatic Disease

Role: lead

NCT02067858Not ApplicableTerminated

An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System

Role: lead

All 4 trials loaded